HDL particle subpopulations: Focus on biological function

BioFactors

Volumn 41, Issue 2, 2015, Pages 67-77

  Rached, Fabiana H ^a,b,c   Chapman, M John ^a   Kontush, Anatol ^a  

^a INSERM   (France)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

Functionality; HDL subpopulations; HDL C

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 3; PHOSPHOLIPID; ANTIOXIDANT; BIOLOGICAL MARKER; FIBRINOLYTIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; VASODILATOR AGENT;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BIOLOGICAL ACTIVITY; CELL PROTECTION; CHOLESTEROL TRANSPORT; ELECTROPHORETIC MOBILITY; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; META ANALYSIS (TOPIC); NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; VASODILATATION; ANIMAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CLASSIFICATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; APOLIPOPROTEIN A-I; BIOMARKERS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CHOLESTEROL, HDL; CYTOPROTECTION; FIBRINOLYTIC AGENTS; GENE EXPRESSION REGULATION; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; VASODILATOR AGENTS;

EID: 84928255156     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1202     Document Type: Review

References (121)

1. Castelli, W. P., Doyle, J. T., Gordon, T., Hames, C. G., Hjortland, M. C., et al. (1977) HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation 55, 767-772.
2. Castelli, W. P., Anderson, K., Wilson, P. W., and Levy, D. (1992) Lipids and risk of coronary heart disease. The Framingham Study. Annal. Epidemiol. 2, 23-28.
3. Sharrett, A. R., Ballantyne, C. M., Coady, S. A., Heiss, G., Sorlie, P. D., et al. (2001) Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 104, 1108-1113.
4. Di Angelantonio, E., Sarwar, N., Perry, P., Kaptoge, S., Ray, K. K., et al. (2009) Major lipids, apolipoproteins, and risk of vascular disease. J. Am. Med. Assoc. 302, 1993-2000.
5. Maron, D. J. (2000) The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am. J. Cardiol. 86, 11L-14L.
6. Gotto, A. M., Jr. and Brinton, E. A. (2004) Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J. Am. Coll. Cardiol. 43, 717-724.
7. Silbernagel, G., Schottker, B., Appelbaum, S., Scharnagl, H., Kleber, M. E., et al. (2013) High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. Eur. Heart J. 34, 3563-3571.
8. Roe, M. T., Ou, F. S., Alexander, K. P., Newby, L. K., Foody, J. M., et al. (2008) Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. Eur. Heart. J. 29, 2480-2488.
9. Bruckert, E., Baccara-Dinet, M., McCoy, F., and Chapman, J. (2005) High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr. Med. Res. Opin. 21, 1927-1934.
10. Toth, P. P., Barter, P. J., Rosenson, R. S., Boden, W. E., Chapman, M. J., et al. (2013) High-density lipoproteins: a consensus statement from the National Lipid Association. J. Clin. Lipidol. 7, 484-525.
11. Camont, L., Chapman, M. J., and Kontush, A. (2011) Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol. Med. 17, 594-603.
12. Mineo, C. and Shaul, P. W. (2012) Novel biological functions of high-density lipoprotein cholesterol. Circ. Res. 111, 1079-1090.
13. Soran, H., Hama, S., Yadav, R., and Durrington, P. N. (2012) HDL functionality. Curr Opin Lipidol. 23, 353-366.
14. Camont, L., Lhomme, M., Rached, F., Le Goff, W., Negre-Salvayre, A., et al. (2013). Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler. Thromb. Vasc. Biol. 33, 2715-2723.
15. Reiner, Z., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M. R., et al. (2011) ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 32, 1769-1818.
16. Eren, E., Yilmaz, N., and Aydin, O. (2012) High density lipoprotein and it's dysfunction. Open Biochem. J. 6, 78-93.
17. Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., et al. (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364, 127-135.
18. Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., et al. (2014) HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 371, 2383-2393.
19. Li, X. M., Tang, W. H., Mosior, M. K., Huang, Y., Wu, Y., et al. (2013) Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler. Thromb. Vasc. Biol. 33, 1696-1705.
20. Keech, A., Simes, R. J., Barter, P., Best, J., Scott, R., et al. (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849-1861.
21. Boden, W. E., Probstfield, J. L., Anderson, T., Chaitman, B. R., Desvignes-Nickens, P., et al. (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365, 2255-2267.
22. Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., et al. (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089-2099.
23. Gordon, S. M., Deng, J., Lu, L. J., and Davidson, W. S. (2010) Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J. Proteome Res. 9, 5239-5249.
24. Vaisar, T., Pennathur, S., Green, P. S., Gharib, S. A., Hoofnagle, A. N., et al. (2007) Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin. Invest. 117, 746-756.
25. Davidson, W. S., Silva, R. A. G. D., Chantepie, S., Lagor, W. R., Chapman, M. J., et al. (2009) Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler. Thromb. Vasc. Biol. 29, 870-876.
26. Wiesner, P., Leidl, K., Boettcher, A., Schmitz, G., and Liebisch, G. (2009) Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J. Lipid Res. 50, 574-585.
27. Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., and Remaley, A. T. (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 13, 423-433.
28. Wagner, J., Riwanto, M., Besler, C., Knau, A., Fichtlscherer, S., et al. (2013) Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs. Arterioscler. Thromb. Vasc. Biol. 33, 1392-1400.
29. Davidson, W. S. and Thompson, T. B. (2007) The structure of apolipoprotein A-I in high density lipoproteins. J. Biol. Chem. 282, 22249-22253.
30. Chapman, M. J., Goldstein, S., Lagrange, D., and Laplaud, P. M. (1981) A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J. Lipid Res. 22:339-358.
31. Joshi, P. H., Toth, P. P., Lirette, S. T., Griswold, M. E., Massaro, J. M., et al. (2014) Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies. Eur. J. Prevent. Cardiol. pii: 2047487314543890.
32. Martin, S. S., Khokhar, A. A., May, H. T., Kulkarni, K. R., Blaha, M. J., et al. (2015) HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. Eur. Heart J. 36, 22-30.
33. Robins, S. J., Collins, D., Wittes, J. T., Papademetriou, V., Deedwania, P. C., et al. (2001) Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. J. Am. Med. Assoc. 285, 1585-1591.
34. Rosenson, R. S., Brewer, H. B., Jr., Chapman, M. J., Fazio, S., Hussain, M. M., et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem. 57, 392-410.
35. Goulinet, S. and Chapman, M. J. (1997) Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 17, 786-796.
36. Asztalos, B. F. and Schaefer, E. J. (2003) High-density lipoprotein subpopulations in pathologic conditions. Am. J. Cardiol. 91, 12E-17E.
37. Miyazaki, O., Ogihara, J., Fukamachi, I., and Kasumi, T. (2014) Evidence for the presence of lipid-free monomolecular apolipoprotein A-1 in plasma. J. Lipid Res. 55, 214-225.
38. Hoofnagle, A. N. and Heinecke, J. W. (2009) Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structure, and function of lipoproteins. J. Lipid Res. 50, 1967-1975.
39. Shah, A. S., Tan, L., Long, J. L., and Davidson, W. S. (2013) Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J. Lipid Res. 54, 2575-2585.
40. Kontush, A., Lhomme, M., and Chapman, M. J. (2013) Unraveling the complexities of the HDL lipidome. J. Lipid Res. 54, 2950-2963.
41. Rosenson, R. S., Brewer, H. B., Jr., Chapman, M. J., Fazio, S., Hussain, M. M., et al. (2011) HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem. 57, 392-410.
42. Rye, K. A. and Barter, P. J. (2004) Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler. Thromb. Vasc. Biol. 24, 421-428.
43. Rothblat, G. H. and Phillips, M. C. (2010). High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr. Opin. Lipidol. 21, 229-238.
44. von Eckardstein, A., Nofer, J. R., and Assmann, G. (2001) High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 21, 13-27.
45. Chapman, M. J., Le Goff, W., Guerin, M., and Kontush, A. (2010). Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur. Heart J. 31, 149-164.
46. Curtiss, L. K., Valenta, D. T., Hime, N. J., and Rye, K. A. (2006) What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler. Thromb. Vasc. Biol. 26, 12-19.
47. Martinez, L. O., Jacquet, S., Esteve, J. P., Rolland, C., Cabezon, E., et al. (2003) Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 421, 75-79.
48. Martinez, L. O., Najib, S., Perret, B., Cabou, C., and Lichtenstein, L. (2015) Ecto-F-ATPase/P2Y pathways in metabolic and vascular functions of high density lipoproteins. Atherosclerosis 238, 89-100.
49. Kontush, A. and Chapman, M. J. (2006) Functionally defective HDL: a new therapeutic target at the crossroads of dyslipidemia, inflammation and atherosclerosis. Pharmacol. Rev. 3, 342-374.
50. Kontush, A. and Chapman, M. J. (2006) Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat. Clin. Pract. Cardiovasc. Med. 3, 144-153.
51. Adorni, M. P., Zimetti, F., Billheimer, J. T., Wang, N., Rader, D. J., et al. (2007) The roles of different pathways in the release of cholesterol from macrophages. J. Lipid Res. 48, 2453-2462.
52. Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, T., and Wang, N. (2008) HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 7, 365-375.
53. Hayden, M. R., Clee, S. M., Brooks-Wilson, A., Genest, J., Jr., Attie, A., et al. (2000) Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. Curr Opin Lipidol. 11, 117-122.
54. Oram, J. F. (2002) Molecular basis of cholesterol homeostasis: lessons from Tangier disease and ABCA1. Trends. Mol. Med. 8, 168-173.
55. Repa, J. J. and Mangelsdorf, D. J. (2002) The liver X receptor gene team: potential new players in atherosclerosis. Nat. Med. 8, 1243-1248.
56. Wang, N., Lan, D., Chen, W., Matsuura, F., and Tall, A. R. (2004) ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 101, 9774-9779.
57. Kennedy, M. A., Barrera, G. C., Nakamura, K., Baldan, A., Tarr, P., et al. (2005) ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell. Metab. 1, 121-131.
58. Wang, N., Ranalletta, M., Matsuura, F., Peng, F., and Tall, A. R. (2006) LXR-induced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass efflux to HDL. Arterioscler. Thromb. Vasc. Biol. 26, 1310-1316.
59. Rothblat, G. H., de la Llera-Moya, M., Atger, V., Kellner-Weibel, G., Williams, D. L., et al. (1999) Cell cholesterol efflux: integration of old and new observations provides new insights. J. Lipid Res. 40, 781-796.
60. Covey, S. D., Krieger, M., Wang, W., Penman, M., and Trigatti, B. L. (2003) Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells. Arterioscler. Thromb. Vasc. Biol. 23, 1589-1594.
61. Zhang, W., Yancey, P. G., Su, Y. R., Babaev, V. R., Zhang, Y., et al. (2003) Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation. 108, 2258-2263.
62. Zhang, Y., Zanotti, I., Reilly, M. P., Glick, J. M., Rothblat, G. H., et al. (2003) Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 108, 661-663.
63. Tricerri, A., Corsico, B., Toledo, J. D., Garda, H. A., and Brenner, R. R. (1998) Conformation of apolipoprotein AI in reconstituted lipoprotein particles and particle-membrane interaction: effect of cholesterol. Biochim. Biophys. Acta. 1391, 67-78.
64. Rotllan, N., Ribas, V., Calpe-Berdiel, L., Martin-Campos, J. M., Blanco-Vaca, F., et al. (2005) Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo. Arterioscler. Thromb. Vasc. Biol. 25, e128-e132.
65. Lewis, G. F. and Rader, D. J. (2005) New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96, 1221-1232.
66. Westerterp, M., Van Eck, M., de Haan, W., Offerman, E. H., Van Berkel, T. J., et al. (2007) Apolipoprotein CI aggravates atherosclerosis development in ApoE-knockout mice despite mediating cholesterol efflux from macrophages. Atherosclerosis 195, e9-e16.
67. Efrat, M. and Aviram, M. (2010) Paraoxonase 1 Interactions with HDL, antioxidants and macrophages regulate atherogenesis-a protective role for HDL phospholipids. Adv. Exp. Med. Biol. 660, 153-166.
68. Hara, S., Shike, T., Takasu, N., and Mizui, T. (1997) Lysophosphatidylcholine promotes cholesterol efflux from mouse macrophage foam cells. Arterioscler. Thromb. Vasc. Biol. 17, 1258-1266.
69. Huang, R., Silva, R. A., Jerome, W. G., Kontush, A., Chapman, M. J., et al. (2011) Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat. Struct. Mol. Biol. 18, 416-422.
70. Yancey, P. G., de la Llera-Moya, M., Swarnakar, S., Monzo, P., Klein, S. M., et al. (2000) High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J. Biol. Chem. 275, 36596-36604.
71. Davidson, W. S., Gillotte, K. L., Lund-Katz, S., Johnson, W. J., Rothblat, G. H., et al. (1995) The effect of high density lipoprotein phospholipid acyl chain composition on the efflux of cellular free cholesterol. J. Biol. Chem. 270, 5882-5890.
72. Marmillot, P., Patel, S., and Lakshman, M. R. (2007) Reverse cholesterol transport is regulated by varying fatty acyl chain saturation and sphingomyelin content in reconstituted high-density lipoproteins. Metabolism 56, 251-259.
73. Favari, E., Calabresi, L., Adorni, M. P., Jessup, W., Simonelli, S., et al. (2009) Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry 48, 11067-11074.
74. de la Llera-Moya, M., Drazul-Schrader, D., Asztalos, B. F., Cuchel, M., Rader, D. J., et al. (2010) The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler. Thromb. Vasc. Biol. 30, 796-801.
75. Kontush, A., Therond, P., Zerrad, A., Couturier, M., Negre-Salvayre, A., et al. (2007) Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler. Thromb. Vasc. Biol. 27, 1843-1849.
76. Miyazaki, M., Nakano, M., Fukuda, M., and Handa, T. (2009) Smaller discoidal high-density lipoprotein particles form saddle surfaces, but not planar bilayers. Biochemistry 48, 7756-7763.
77. Huang, Y., DiDonato, J. A., Levison, B. S., Schmitt, D., Li, L., et al. 2014. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat. Med. 20, 193-203.
78. Navab, M., Ananthramaiah, G. M., Reddy, S. T., Van Lenten, B. J., Ansell, B. J., et al. (2004) The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J. Lipid Res. 45, 993-1007.
79. Van Lenten, B. J., Navab, M., Shih, D., Fogelman, A. M., Lusis, A. J. (2001) The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc. Med. 11, 155-161.
80. Navab, M., Ananthramaiah, G. M., Reddy, S. T., Van Lenten, B. J., Ansell, B. J., et al. (2004) The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J. Lipid Res. 45, 993-1007.
81. Kontush, A., Chantepie, S., and Chapman, M. J. (2003) Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23, 1881-1888.
82. Stocker, R., Keaney, J. F., Jr. (2004) Role of oxidative modifications in atherosclerosis. Physiol Rev. 84, 1381-1478.
83. Kontush, A. and Chapman, M. J. (2010) Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr. Opin. Lipidol. 21, 312-318.
84. Zerrad-Saadi, A., Therond, P., Chantepie, S., Couturier, M., Rye, K.-A., et al. (2009) HDL3-Mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 29, 2169-2175.
85. Garner, B., Waldeck, A. R., Witting, P. K., Rye, K. A., and Stocker, R. (1998) Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J. Biol. Chem. 273, 6088-6095.
86. Chantepie, S., Malle, E., Sattler, W., Chapman, M. J., and Kontush, A. (2009) Distinct HDL subclasses present similar intrinsic susceptibility to oxidation by HOCl. Arch. Biochem. Biophys. 487, 28-35.
87. Navab, M., Berliner, J. A., Subbanagounder, G., Hama, S., Lusis, A. J., et al. (2001) HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 21, 481-488.
88. Boisfer, E., Stengel, D., Pastier, D., Laplaud, P. M., Dousset, N., et al. (2002) Antioxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II. J. Lipid Res. 43, 732-741.
89. Ribas, V., Sanchez-Quesada, J. L., Anton, R., Camacho, M., Julve, J., et al. (2004) Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Circ. Res. 95, 789-797.
90. Ostos, M. A., Conconi, M., Vergnes, L., Baroukh, N., Ribalta, J., et al. (2001) Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21, 1023-1028.
91. Davignon, J. (2005) Apolipoprotein E and atherosclerosis: beyond lipid effect. Arterioscler. Thromb. Vasc. Biol. 25, 267-269.
92. Navab, M., Hama, L. S., Van L. B., Fonarow G. C., Cardinez C. J., et al. (1997) Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J. Clin. Invest. 99, 2005-2019.
93. Trougakos, I. P., Lourda, M., Agiostratidou, G., Kletsas, D., and Gonos, E. S. (2005) Differential effects of clusterin/apolipoprotein J on cellular growth and survival. Free Rad. Biol. Med. 38, 436-449.
94. Dahlback, B. and Nielsen, L. B. (2009) Apolipoprotein M affecting lipid metabolism or just catching a ride with lipoproteins in the circulation? Cell Mol. Life Sci. 66, 559-564.
95. Watson, A. D., Navab, M., Hama, S. Y., Sevanian, A., Prescott, S. M., et al. (1995) Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J. Clin. Invest. 95, 774-782.
96. Rallidis, L. S., Tellis, C. C., Lekakis, J., Rizos, I., Varounis, C., et al. (2012) Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up. J. Am. Coll. Cardiol. 60, 2053-2060.
97. Kontush, A., Chantepie, S., and Chapman, M. J. (2003) Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23, 1881-1888.
98. Shuhei, N., Soderlund, S., Jauhiainen, M., and Taskinen, M. R. (2010) Effect of HDL composition and particle size on the resistance of HDL to the oxidation. Lipids Health Dis. 9, 104.
99. Nicholls, S. J., Dusting, G. J., Cutri, B., Bao, S., Drummond, G. R., et al. (2005) Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation. 111, 1543-1550.
100. Yvan-Charvet, L., Wang, N., and Tall, A. R. (2010) Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler. Thromb. Vasc. Biol. 30, 139-143.
101. Shaw, J. A., Bobik, A., Murphy, A., Kanellakis, P., Blombery, P., et al. (2008) Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ. Res. 103, 1084-1091.
102. Nofer, J.-R. and Assmann, G. (2005) Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc. Med. 15, 265-271.
103. Rye, K.-A., Bursill, C. A., Lambert, G., Tabet, F., and Barter, P. J. (2009) The metabolism and anti-atherogenic properties of HDL. J. Lipid Res. 50, S195-S200.
104. Xia, P., Vadas, M. A., Rye, K. A., Barter, P. J., and Gamble, J. R. (1999) High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J. Biol. Chem. 274, 33143-33147.
105. Nicholls, S. J., Lundman, P., Harmer, J. A., Cutri, B., Griffiths, K. A., et al. (2006) Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. J. Am. Coll. Cardiol. 48, 715-720.
106. Nofer, J. R., Levkau, B., Wolinska, I., Junker, R., Fobker, M., et al. (2001) Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J. Biol. Chem. 276, 34480-34485.
107. Riwanto, M., Rohrer, L., Roschitzki, B., Besler, C., Mocharla, P., et al. (2013) Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 127, 891-904.
108. de Souza, J. A., Vindis, C., Negre-Salvayre, A., Rye, K. A., Couturier, M., et al. (2010) Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I. J. Cell Mol. Med. 14, 608-620.
109. de Souza, J. A., Vindis, C., Hansel, B., Negre-Salvayre, A., Therond, P., et al. (2008) Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. Atherosclerosis 197, 84-94.
110. Calabresi, L., Gomaraschi, M., and Franceschini, G. (2003) Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler. Thromb. Vasc. Biol. 23, 1724-1731.
111. Mineo, C., Deguchi, H., Griffin, J. H., and Shaul, P. W. (2006) Endothelial and antithrombotic actions of HDL. Circ Res. 98, 1352-1364.
112. Drew, B. G., Fidge, N. H., Gallon-Beaumier, G., Kemp, B. E., and Kingwell, B. A.(2004) High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc Natl Acad Sci U S A 101, 6999-7004.
113. Nofer, J. R., van der Giet, M., Tolle, M., Wolinska, I., von Wnuck Lipinski, K., et al. (2004) HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 113, 569-581.
114. Tatematsu, S., Francis, S. A., Natarajan, P., Rader, D. J., Saghatelian, A., et al. (2013) Endothelial lipase is a critical determinant of high-density lipoprotein-stimulated sphingosine 1-phosphate-dependent signaling in vascular endothelium. Arterioscler. Thromb. Vasc. Biol. 33, 1788-1794.
115. Christoffersen, C., Obinata, H., Kumaraswamy, S. B., Galvani, S., Ahnstrom, J., et al. (2011) Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc. Natl. Acad. Sci. U S A 108, 9613-9618.
116. Sattler, K. and Levkau, B. (2009) Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc. Res. 82, 201-211.
117. Egom, E. E., Mamas, M. A., and Soran, H. (2013). HDL quality or cholesterol cargo: what really matters-spotlight on sphingosine-1-phosphate-rich HDL. Curr. Opin. Lipid. 24, 351-356.
118. Nofer, J. R., Brodde, M. F., and Kehrel, B. E. (2010) High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clin Exp Pharmacol Physiol 37, 726-735.
119. Nofer, J. R., Kehrel, B., Fobker, M., Levkau, B., Assmann, G., et al. (2002) HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161, 1-16.
120. Dole, V. S., Matuskova, J., Vasile, E., Yesilaltay, A., Bergmeier, W., et al. (2008) Thrombocytopenia and platelet abnormalities in high-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 28, 1111-1116.
121. Nofer, J. R., Walter, M., Kehrel, B., Wierwille, S., Tepel, M., et al. (1998) HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1, 2-diacylglycerol and inositol 1, 4, 5-tris-phosphate. Arterioscler. Thromb. Vasc. Biol. 18, 861-869.